

UCSF Helen Diller Family
Comprehensive
Cancer Center

Adult Cancers

Breast (24 trials)
Cutaneous (13 trials)
Gastrointestinal (15 trials)
Genitourinary (29 trials)
Gynecological (5 trials)
Head and Neck (7 trials)
Malignant Hematology (31 trials)
Multiple / Ill-Defined Disease Sites (14 trials)
Neurologic Oncology (8 trials)
Thoracic (12 trials)
Other Trials (92 trials)
Total Trials = 250

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Prevention					
16752	NCT02620852	Esserman, Laura	The WISDOM Study (Women Informed to Screen Depending on Measures of Risk)	Screening	Choy@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer					
187523	NCT03344965	Melisko, Michelle	A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"	Treatment	Amy.Deluca@ucsf.edu
EA-RUGO-5142020	NCT04395508	Rugo, Hope	EXPANDED ACCESS, SINGLE-ARM, MULTICENTER STUDY TO PROVIDE AT HOME SUBCUTANEOUS ADMINISTRATION OF PERTUZUMAB AND TRASTUZUMAB FIXED-DOSE COMBINATION (PH FDC SC) FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER DURING THE COVID-19 PANDEMIC	Other	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Early Stage Breast Cancer					
167514	NCT03094052	Chien, Jo	An open label study to characterize the incidence and severity of diarrhea in patients with HER2+ breast cancer treated with neratinib with or without trastuzumab	Treatment	Amy.Deluca@ucsf.edu
16704	NCT02872025	Esserman, Laura	Testing the Ability of Pembrolizumab and mRNA 2752 to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS	Treatment	Amy.Deluca@ucsf.edu; Tristan.Loveday@ucsf.edu
19753	NCT03562637	Melisko, Michelle	The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Radiation					
117515	NCT01570998	Alvarado, Michael	Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy following Breast-Conserving Surgery	Treatment	Amy.Deluca@ucsf.edu; Stig.Kreps@ucsfmedctr.org

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Advanced Breast Cancer > ER+					
19754	NCT03858972	Rugo, Hope	Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane	Treatment	Amy.Deluca@ucsf.edu
20757	NCT04305496	Rugo, Hope	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)	Treatment	Amy.Deluca@ucsf.edu
197511	NCT03781063	Rugo, Hope	An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Treatment	Amy.Deluca@ucsf.edu
187526	NCT03250676	Munster, Pamela	A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer	Treatment	Amy.Deluca@ucsf.edu
18751	NCT03326102	Melisko, Michelle	A Multi-center, Open-Label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer	Treatment	Amy.Deluca@ucsf.edu
197520	NCT04190056	Munster, Pamela	Epigenetic priming for Immune therapy in ER-positive breast cancer in biomarker select population	Treatment	Amy.Deluca@ucsf.edu
157521	NCT03095352	Rugo, Hope	A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > HER2+					
157521	NCT03095352	Rugo, Hope	A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease	Treatment	Amy.Deluca@ucsf.edu
197516	NCT04042701	Rugo, Hope	A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, In Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)	Treatment	Amy.Deluca@ucsf.edu
20754	NCT03975647	Chien, Jo	Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer(HER2CLIMB-02)	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive					
187513	NCT03422003	Park, Catherine	Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma	Supportive Care	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Advanced Breast Cancer > Triple Negative					
207516	NCT04461600	Rugo, Hope	TENACITY: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer	Treatment	Amy.Deluca@ucsf.edu
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
197525	NCT04191135	Rugo, Hope	An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)	Treatment	Amy.Deluca@ucsf.edu
157521	NCT03095352	Rugo, Hope	A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > Brain Metastases/leptomeningeal dz					
197515	NCT03501979	Melisko, Michelle	A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer	Treatment	Amy.Deluca@ucsf.edu
17752	NCT02915744	Melisko, Michelle	A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Neoadjuvant					
097517	NCT01042379	Chien, Jo	I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2)	Treatment	Amy.Deluca@ucsf.edu; adi.goldman@ucsf.edu; anika.christofferson@ucsf.edu
177539	NCT02206984	Mukhtar, Rita	A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer	Treatment	Amy.Deluca@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Cutaneous > Melanoma					
18859	NCT03820986	Daud, Adil	A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)	Treatment	arielle.oglesby@ucsf.edu
20863	NCT04598009	Tsai, Katy	A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant melanoma	Treatment	arielle.oglesby@ucsf.edu
19854	NCT03684785	Daud, Adil	A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab in Patients with Advanced Solid Tumors	Treatment	arielle.oglesby@ucsf.edu
19855	NCT04135352	Daud, Adil	A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of V938 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic or Recurrent Malignancies	Treatment	arielle.oglesby@ucsf.edu
18851	NCT03132675	Tsai, Katy	A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)	Treatment	Katy.Tsai@ucsf.edu; Roman.Zingarelli@ucsf.edu; arielle.oglesby@ucsf.edu
20853	NCT04417621	Daud, Adil	A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma	Treatment	arielle.oglesby@ucsf.edu
19859	NCT03899155	Daud, Adil	Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab	Treatment	arielle.oglesby@ucsf.edu
Cutaneous > Merkel Cell Carcinoma					
18861	NCT03599713	Daud, Adil	A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)	Treatment	arielle.oglesby@ucsf.edu
19862	NCT03853317	Daud, Adil	A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor	Treatment	arielle.oglesby@ucsf.edu
Cutaneous > Squamous Cell Carcinoma					
20864	NCT04349436	Tsai, Katy	An Open-Label, Multicenter, Phase 1B Study of RP1 in Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma	Treatment	arielle.oglesby@ucsf.edu
Cutaneous > Melanoma > Locally Advanced/ Metastatic					
18855	NCT03484923	Daud, Adil	A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma	Treatment	Adil.Daud@ucsf.edu; Roman.Zingarelli@ucsf.edu; arielle.oglesby@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Cutaneous > Melanoma > Immunotherapy					
18991	NCT03486873	Daud, Adil	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial	Treatment	Adil.Daud@ucsf.edu; Roman.Zingarelli@ucsf.edu
Cutaneous > Melanoma > Molecularly Targeted					
20958	NCT04418167	Dhawan, Mallika	A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the Treatment of Advanced Solid Tumors with MAPK Pathway Mutations	Treatment	1-877-827-3222
Cutaneous > Melanoma > Immunotherapy > Prior Immunotherapy					
18851	NCT03132675	Tsai, Katy	A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)	Treatment	Katy.Tsai@ucsf.edu; Roman.Zingarelli@ucsf.edu; arielle.oglesby@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Pancreatic Cancer					
20456	NCT04229004	Ko, Andrew	Precision Promise Platform Trial For Metastatic Pancreatic Cancer	Treatment	madeline.griffith@ucsf.edu; malori.mindo@ucsf.edu
Gastrointestinal > Neuroendocrine Tumors (NET)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Rectal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Neuroendocrine Tumors (NET) > Well-Differentiated Neuroendocrine Tumor					
ALLIANCE-A021602	NCT03375320	Bergsland, Emily	RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY (CABINET)	Treatment	khuong.le@ucsf.edu
Gastrointestinal > Rectal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Gastrointestinal Stromal Tumor (GIST) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
204520	NCT04363801	Ko, Andrew	A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)	Treatment	taylor.sanchez@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Anal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Anal Cancer > Prevention / Dysplasia					
AMC-A01	NCT02135419	Palefsky, Joel	ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study	Prevention	1-877-827-3222
Gastrointestinal > Pancreatic Cancer > Metastatic					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	luchia.andemicael@ucsf.edu
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Advanced (including Locally Advanced / Inoperable and Metastatic) > First-Line					
18453	NCT03504397	Ko, Andrew	A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Treatment	Mikaela.Esquivel@ucsf.edu
Gastrointestinal > Anal Cancer > Localized > HIV Positive					
AMC-092	NCT02437851	Berry, Michael	A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Positive Persons	Treatment	Arezou.SadighiAkha@ucsf.edu
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Resectable > Neoadjuvant (before surgery)					
17701	NCT03165994	Ko, Andrew	A Phase 2 Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers	Treatment	andrew.chon@ucsf.edu
Gastrointestinal > Anal Cancer > Localized > HIV Positive					
AMC-088	NCT02059499	Jay, Naomi	A Randomized, Phase III Study of Intra-Anal Imiquimod 2.5% vs. Topical 5-Fluorouracil 5% vs. Observation for the Treatment of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Positive Men and Women	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced > Second-Line and Beyond					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma) > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond					
15452	NCT02150967	Kelley, Robin	A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations who Failed or are Intolerant to Platinum-based Chemotherapy	Treatment	madeline.griffith@ucsf.edu
Gastrointestinal > Rectal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond					
174517	NCT03396926	Atreya, Chloe	Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer	Treatment	1-877-827-3222
Gastrointestinal > Neuroendocrine Tumors (NET) > High Grade / Poorly Differentiated Neuroendocrine Carcinoma > Metastatic / Unresectable					
17459	NCT02724540	Fidelman, Nicholas	Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A phase 2 randomized multicenter trial to compare hepatic progression-free survival following bland embolization, lipiodol chemoembolization, and drug-eluting bead chemoembolization of neuroendocrine liver metastases	Treatment	shawn.cheng@ucsf.edu
Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond					
174517	NCT03396926	Atreya, Chloe	Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer	Treatment	1-877-827-3222
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma) > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond					
209511	NCT04526106	Kelley, Robin	A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors	Treatment	nana.owusu-kwarteng@ucsf.edu
Gastrointestinal > Neuroendocrine Tumors (NET) > Well-Differentiated Neuroendocrine Tumor > Pancreatic NET > Metastatic / Unresectable > Liver-Directed					
17705	NCT03457948	Fidelman, Nicholas	A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases	Treatment	andrew.chon@ucsf.edu
Gastrointestinal > Neuroendocrine Tumors (NET) > Well-Differentiated Neuroendocrine Tumor > Carcinoid > Metastatic / Unresectable > Liver-Directed Therapy					
17705	NCT03457948	Fidelman, Nicholas	A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases	Treatment	andrew.chon@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Bladder Cancer					
20524	NCT04601857	Koshkin, Vadim	A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma	Treatment	patricia.li@ucsf.edu
Genitourinary > Prostate Cancer					
135512	NCT02435472	Chan, June	A Randomized Clinical Trial of Exercise versus Usual Care among Men Opting for Active Surveillance for Prostate Cancer (AS Exercise RCT)	Supportive Care	1-877-827-3222
NRG-GU008	NCT04134260	Mohamad, Osama	RANDOMIZED PHASE III TRIAL INCORPORATING ABIRATERONE ACETATE WITH PREDNISONE AND APALUTAMIDE AND ADVANCED IMAGING INTO SALVAGE TREATMENT FOR PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY	Treatment	luchia.andemicael@ucsf.edu
20952	NCT04574401	Carroll, Peter	A Phase 1 Safety and Efficacy Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy Using the da Vinci® Surgical System with Firefly® Fluorescent Imaging	Other	Phu.Lam@ucsf.edu
17553	NCT03397160	Carroll, Peter	Pioneering Advances in Care & Education (PACE)	Supportive Care	1-877-827-3222
20553	NCT04763980	Borno, Hala	Navigate Study: use of a community-based Health Coach to improve access to germline genetic testing among African American men with prostate cancer	Health Services Research	1-877-827-3222
175513	NCT03999151	Kenfield, Stacey	A Randomized Controlled Trial of Diet & Exercise Interventions among Men with Prostate Cancer - II (Prostate 8 - II)	Prevention	1-877-827-3222
20727	NCT03809000	Wong, Anthony	RTOG 3506 STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features	Treatment	1-877-827-3222
Genitourinary > Renal Cell Carcinoma					
19707	NCT03926013	Aggarwal, Rahul	A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081, in Subjects with Advanced Stage Solid Tumors	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
18525	NCT04258462	Wang, Jane Zhen	Hyperpolarized 13C pyruvate metabolic MRI to predict renal tumor aggressiveness	Diagnostic	namasvi.jariwala@ucsf.edu
Genitourinary > Testicular Cancer					
AGCT1531	NCT03067181	Rangaswami, Arun	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Treatment	1-877-827-3222
Genitourinary > Prostate Cancer > Non-Metastatic Castration Sensitive (Rising PSA)					
165513	NCT03009981	Aggarwal, Rahul	A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer	Treatment	brian.ma2@ucsf.edu; patricia.li@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Prostate Cancer > Metastatic Castration Sensitive					
155513		Carroll, Peter	A Randomized Controlled Clinical Trial of a Smartphone-Based App to Improve Urinary and Sexual Function Outcomes after Robot-Assisted Laparoscopic Radical Prostatectomy Surgery	Supportive Care	1-877-827-3222
16703	NCT03007732	Fong, Lawrence	Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination with Intratumoral SD-101 Therapy in Patients with Hormone-Naïve Oligometastatic Prostate Cancer Receiving Definitive Prostatic Radiation and Intermittent Androgen Deprivation Therapy	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu; marissa.gin@ucsf.edu
Genitourinary > Bladder Cancer > Metastatic					
175211	NCT03288545	Friedlander, Terence	A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer	Treatment	patricia.li@ucsf.edu
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC)					
189517	NCT03822871	Aggarwal, Rahul	A Phase 1 Trial for Evaluation of Safety and 177Lu Radiation Dosimetry of CTT1403: A Peptidomimetic Inhibitor of Prostate Specific Membrane Antigen, in Metastatic Castration Resistant Prostate Cancer (mCRPC)	Treatment	1-877-827-3222
187014	NCT03577028	Fong, Lawrence	A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
145512	NCT02391025	Aggarwal, Rahul	Gallium-68 Citrate PET To Detect MYC Amplification in Metastatic Castrate Resistant Prostate Cancer	Diagnostic	1-877-827-3222
155518	NCT02735252	Aggarwal, Rahul	Precision Oncology and Molecular Targeting in Advanced Genitourinary Cancers: Identifying Predictive Markers of Response (The "PROMOTE" Study)	Basic Science	patricia.li@ucsf.edu
18954	NCT03575819	Aggarwal, Rahul	A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)	Treatment	claire.hooker@ucsf.edu
175519	NCT03503344	Aggarwal, Rahul	A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients with Oligometastatic Disease on PSMA-PET Imaging	Treatment	patricia.li@ucsf.edu
20955	NCT04253262	Aggarwal, Rahul	A Phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer	Treatment	melissa.lopez@ucsf.edu
19707	NCT03926013	Aggarwal, Rahul	A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081, in Subjects with Advanced Stage Solid Tumors	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
199510	NCT04145375	Aggarwal, Rahul	Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol	Treatment	1-877-827-3222
Genitourinary > Prostate Cancer > Localized > Pre-Therapy / Neoadjuvant					
18702	NCT03821246	Fong, Lawrence	An open-label multi-center phase II study of neoadjuvant atezolizumab-based combination therapy in men with localized prostate cancer prior to radical prostatectomy	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Renal Cell Carcinoma > Second Line > Post Checkpoint Inhibitor					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Genitourinary > Prostate Cancer > Localized > Adjuvant					
175516	NCT03933670	Aggarwal, Rahul	A Phase 2 Study of Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) in Patients with Prostate Cancer on Active Surveillance	Diagnostic	1-877-827-3222
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Resistant					
16557	NCT03248570	Fong, Lawrence	Phase 2 open label study of pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC) with or without DNA damage repair defects	Treatment	patricia.li@ucsf.edu
185511	NCT03805594	Aggarwal, Rahul	Immunogenic Priming with PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination with Pembrolizumab	Treatment	patricia.li@ucsf.edu
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Resistant					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Genitourinary > Bladder Cancer > Metastatic > Prior Chemotherapy and/or Prior Immunotherapy					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Variant Histology					
19551	NCT03910660	Aggarwal, Rahul	Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype	Treatment	patricia.li@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal					
174017	NCT03857087	Ohliger, Michael	Gallium-68 Prostate Specific Membrane Antigen for Ovarian Cancer: A Pilot Feasibility Study	Diagnostic	1-877-827-3222
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > First Line					
AGCT1531	NCT03067181	Rangaswami, Arun	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Treatment	1-877-827-3222
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > Progressive/Recurrent					
19401	NCT03673124	Chen, Lee-may	A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum	Treatment	1-877-827-3222
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > Progressive/Recurrent > Platinum Resistant					
NRG-GY009	NCT02839707	Alvarez, Edwin	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	Treatment	1-877-827-3222
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > First Line > Stage IV					
NRG-GY019	NCT04095364	Chen, Lee-may	A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx)					
172021	NCT03823131	Heaton, Chase	The Trifecta Study: Optimizing Antitumor Immunity Using Tavokinogene Telseplasmid with Electroporation, Pembrolizumab, and Epcadostat in Squamous Cell Carcinoma of the Head and Neck	Treatment	carter.hultman@ucsf.edu
Head and Neck > Nasopharyngeal					
CTSU-NRG-HN001	NCT02135042	Yom, Sue	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Treatment	carter.hultman@ucsf.edu
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional					
CTSU-NRG-HN004	NCT03258554	Yom, Sue	NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin	Treatment	carter.hultman@ucsf.edu
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Nasopharyngeal Carcinoma (NPC)					
162010	NCT03267498	Yom, Sue	Nivolumab in Combination with Chemoradiation for Patients with Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study with Correlative Biomarkers	Treatment	carter.hultman@ucsf.edu
CTSU-NRG-HN001	NCT02135042	Yom, Sue	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Treatment	carter.hultman@ucsf.edu
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Metastatic > All others					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional > No Prior Therapy > Peri Operative					
16201	NCT03153982	Ryan, William	Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition with Ruxolitinib in Operable Head and Neck Cancer: A Window Trial	Treatment	carter.hultman@ucsf.edu
177018	NCT03708224	Algazi, Alain	A Phase II Study of Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Acute Myeloid Leukemia (AML)					
172521	NCT03013998	Olin, Rebecca	A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)	Treatment	Jenai.Wilmoth@ucsf.edu
20256	NCT04336982	Smith, Catherine	AN EXPLORATORY PHASE 1B OPEN-LABEL MULTI-ARM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CC-90009 IN COMBINATION WITH ANTI-LEUKEMIA AGENTS IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA	Treatment	1-877-827-3222
Malignant Hematology > Chronic Myeloid Leukemia (CML)					
202510	NCT04605211	Schoenbeck, Kelly	Being Present-MPN: A Distress Reduction Intervention for Patients with BCR-ABL-Negative MPNs and CML on Tyrosine Kinase Inhibitors	Supportive Care	1-877-827-3222
Malignant Hematology > Non-Hodgkin Lymphoma (NHL)					
16252	NCT02445222	Andreadis, Charalambos	Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy	Other	Jenai.Wilmoth@ucsf.edu
ECOG-ACRIN-EA4151	NCT03267433	Kaplan, Lawrence	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission	Treatment	Jenai.Wilmoth@ucsf.edu
187017	NCT03598608	Andreadis, Charalambos	A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies	Treatment	andrew.chon@ucsf.edu
192516	NCT01796171	Hernandez Pampaloni, Miguel	A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radiionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.	Treatment	Luis.Camacho@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM)					
202511	NCT04589286	Banerjee, Rahul	Phase II Study of Digital Life Coaching in Multiple Myeloma Patients Undergoing Stem Cell Transplantation	Supportive Care	1-877-827-3222
Malignant Hematology > Multiple Myeloma (MM) > Untreated					
192513	NCT03901963	Shah, Nina	A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant	Treatment	1-877-827-3222
Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative					
197019	NCT04136756	Shah, Nina	A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 as a Single Agent in Relapsed or Refractory Hematological Malignancies	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Amyloidosis > Untreated					
202516	NCT04512235	Chung, Alfred	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Acute Myeloid Leukemia (AML) > Untreated					
202517	NCT04231851	Mittal, Varun	Phase II study of the combination of CPX-351 and Glasdegib in previously untreated patients with Acute Myelogenous Leukemia with MDS related changes or therapy-related Acute myeloid leukemia: A University of California Hematologic Malignancies Consortium Protocol (UCHMC1913/UCI 18-105)	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
189512	NCT03650491	Wong, Sandy	A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)	Treatment	ann.chan@ucsf.edu
202524	NCT03145181	Martin, Tom	A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma	Treatment	Jenai.Wilmoth@ucsf.edu
139511	NCT02332850	Martin, Tom	A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination with Standard Carfilzomib, and High-dose weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Hodgkin Disease > Relapsed / Refractory					
AMC-097	NCT02797470	Kaplan, Lawrence	A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
EA-GSK-213304-WONG	NCT03763370	Wong, Sandy	Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody	Other	1-877-827-3222
18951	NCT03424603	Shah, Nina	A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies	Treatment	1-877-827-3222
Malignant Hematology > Chronic Lymphocytic Leukemia (CLL) > Relapsed / Refractory					
18707	NCT03331198	Fakhri, Bitu	An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
202528	NCT04549363	Wong, Sandy	Characterization of Corneal Epithelial Changes in Participants Treated with Belantamab Mafodotin (GSK2857916): A Companion Study	Treatment	Jenai.Wilmoth@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Myelodysplastic Syndromes (MDS) > Relapsed / Refractory					
177012	NCT02152956	Sayre, Peter	A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome	Treatment	Julie.McCluggage@ucsf.edu; seung-ha.seo@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
20255	NCT04133636	Wong, Sandy	A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma	Treatment	1-877-827-3222
Malignant Hematology > Acute Myeloid Leukemia (AML) > Relapsed / Refractory					
192514	NCT03904251	Damon, Lloyd	A Phase 1b Trial with Dose Expansion Evaluating CPX-351 plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous Leukemia	Treatment	1-877-827-3222
207019	NCT03190278	Olin, Rebecca	Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with Relapsed/Refractory Acute Myeloid Leukemia	Treatment	Julie.McCluggage@ucsf.edu
169522	NCT03194685	Smith, Catherine	A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia	Treatment	Phu.Lam@ucsf.edu
177012	NCT02152956	Sayre, Peter	A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome	Treatment	Julie.McCluggage@ucsf.edu; seung-ha.seo@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory > 3 or More Prior Lines of Therapy					
18704	NCT03486067	Wong, Sandy	A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
187016	NCT03601078	Shah, Nina	A Phase 2, Multicohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMA-2)	Treatment	andrew.chon@ucsf.edu
Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Relapsed / Refractory					
167014	NCT02631044	Andreadis, Charalambos	A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Positive > Relapsed / Refractory					
AMC-097	NCT02797470	Kaplan, Lawrence	A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells	Treatment	Jenai.Wilmoth@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory > 3 or More Prior Lines of Therapy					
197019	NCT04136756	Shah, Nina	A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 as a Single Agent in Relapsed or Refractory Hematological Malignancies	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
197011	NCT03933735	Shah, Nina	A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
197018	NCT04108195	Martin, Tom	A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Relapsed / Refractory > Aggressive					
ALLIANCE-A051301	NCT02443077	Andreadis, Charalambos	A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype	Treatment	Jenai.Wilmoth@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Multiple / III-Defined Disease Sites > Financial Assistance and Reimbursements					
189820	NCT03849742	Braunstein, Steve	Ride to care - A pilot study to investigate the clinical and quality of life benefit of eliminating transportation barriers for disadvantaged cancer patients undergoing ambulatory palliative radiotherapy	Health Services Research	jamese.johnson@ucsf.edu; luchia.andemicael@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Multiple / III-Defined Disease Sites > Solid Tumors					
186514	NCT03634982	Munster, Pamela	A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
18956	NCT03590054	Aggarwal, Rahul	A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies	Treatment	claire.hooker@ucsf.edu
176510	NCT03157128	Kang, Hyunseok	A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
189515	NCT03600883	Munster, Pamela	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)	Treatment	ann.chan@ucsf.edu
11955	NCT01543763	Munster, Pamela	Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination with PCI-24781 in Patients with Metastatic Solid Tumors	Treatment	melissa.lopez@ucsf.edu
AMC-095	NCT02408861	Wang, Chia-Ching	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Treatment	claire.hooker@ucsf.edu
20806	NCT04697524	Cheng, Stephanie	Integrative Palliative Care/Psycho-oncology Telehealth Group Medical Visits for Patients with Advanced Cancer: A Pilot Study	Supportive Care	austin.fan@ucsf.edu
189510	NCT03682289	Aggarwal, Rahul	Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies	Treatment	claire.hooker@ucsf.edu
18959	NCT03678883	Munster, Pamela	Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3beta) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors	Treatment	ann.chan@ucsf.edu
20929	NCT04621435	Hope, Thomas	Imaging of Solid Tumors Using 68Ga-FAP-2286	Diagnostic	maya.aslam@ucsf.edu
20951	NCT04171700	Munster, Pamela	A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated with Deleterious Mutations in Homologous Recombination Repair Genes	Treatment	silpa.karipineni@ucsf.edu
207017	NCT04060342	Atreya, Chloe	A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 with Standard of Care or in Combination with an Anti-PD-1 Antibody in Patients with Specified Metastatic Solid Tumors	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu; rebecca.holman@ucsf.edu
19956	NCT03989115	Munster, Pamela	A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Neurologic Oncology > Adult Glioma (Age >= 18)					
13106	NCT03739411	Chang, Susan	Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients with Gliomas	Diagnostic	Jane.Rabbitt@ucsf.edu
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 2 (Low Grade)					
15103	NCT02549833	Taylor, Jennie	Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients with WHO Grade II Glioma	Treatment	Jane.Rabbitt@ucsf.edu; Meghan.Tedesco@ucsf.edu
19103	NCT03948490	Taylor, Jennie	Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas	Supportive Care	1-877-827-3222
15108	NCT02924038	Butowski, Nicholas	Pilot Randomized Pre-Surgical Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine plus Poly-ICLC in Patients with WHO Grade II Low-Grade Glioma (LGG)	Treatment	Jane.Rabbitt@ucsf.edu
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 3 (Anaplastic)					
161011	NCT02796261	Butowski, Nicholas	A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy	Treatment	1-877-827-3222
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Recurrent					
181011	NCT03295396	Butowski, Nicholas	A phase II, open-label study of ONC201 in adults with recurrent high-grade glioma	Treatment	Jane.Rabbitt@ucsf.edu
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 2 (Low Grade) > Recurrent					
20101	NCT04164901	Clarke, Jennifer	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation	Treatment	1-877-827-3222
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Newly diagnosed > Nonsurgical					
20106	NCT03776071	Butowski, Nicholas	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Thoracic > Non-small cell Lung Cancer					
ECOG-ACRIN-EA5163	NCT03793179	Wang, Chia-Ching	EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis	Treatment	Paul.Couey@ucsf.edu
20654	NCT04165083	Gubens, Matthew	KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naive Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
20651	NCT04165096	Gubens, Matthew	KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
20653	NCT04165070	Gubens, Matthew	KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
196511	NCT03906071	Blakely, Collin	A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation					
176518	NCT03318939	Blakely, Collin	A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
206510	NCT04077463	Gubens, Matthew	An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer	Treatment	janna.blaauw@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Stage > Metastatic, stage IV, or inoperable					
18653	NCT03375489	Rabow, Michael	Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer	Supportive Care	lisa.tan@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > ALK (EML4-ALK) Translocation					
166512	NCT03087448	Blakely, Collin	A Phase I/II Study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Stage > Stage III					
17658	NCT03433469	Blakely, Collin	A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients with Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Stage > Stage I/II					
17658	NCT03433469	Blakely, Collin	A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients with Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation > 1st Line					
17658	NCT03433469	Blakely, Collin	A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients with Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Stage > Metastatic, stage IV, or inoperable > 2nd Line and Above					
199516	NCT03829436	Munster, Pamela	A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors	Treatment	1-877-827-3222
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation > 2nd Line and Above					
19655	NCT04085315	Blakely, Collin	A phase I/Ib study of Alisertib in combination with Osimertinib in metastatic EGFR-mutant lung cancer	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
her Trials					
17-23965	NCT03839745	St. Helen, Gideon	Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power	Basic Science	Sundos.Yassin@ucsf.edu
18656	NCT03410043	Blakely, Collin	Randomized Phase II Trial of Local Consolidation Therapy (LCT) after Osimertinib for Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
187011	NCT03454451	Fong, Lawrence	A Phase 1/1b multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with cikoradenant, with pembrolizumab, and with cikoradenant plus pembrolizumab in adult subjects with advanced cancers	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
18208	NCT03719690	Kang, Hyunseok	A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)	Treatment	carter.hultman@ucsf.edu
186517	NCT04005144	Blakely, Collin	A phase I study of brigatinib with binimetinib in advanced ALK- or ROS1-rearranged non-small cell lung cancer (NSCLC)	Treatment	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
19555	NCT03748641	Koshkin, Vadim	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects With Metastatic Prostate Cancer	Treatment	patricia.li@ucsf.edu
19852	NCT02974725	Daud, Adil	A Phase Ib, open-label, multicenter study of oral LXH254-centric combinations in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer or NRAS mutant melanoma	Treatment	arielle.oglesby@ucsf.edu
ALLIANCE-A051701	NCT03984448	Andreadis, Charalambos	Randomized Phase II/III Study of Venetoclax (ABT199) plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas	Treatment	Erika.Cavallone@ucsf.edu
199511	NCT03997968	Munster, Pamela	A MULTI-CENTER, OPEN LABEL PHASE 1/2 STUDY OF CYT-0851, AN ORAL RAD51 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS	Treatment	ann.chan@ucsf.edu
202013	NCT03691207	Kang, Hyunseok	A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients with Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations	Treatment	madeleine.welsh@ucsf.edu
NRG-CC008	NCT04251052	Chen, Lee-may	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]	Prevention	Katherine.bigay@ucsf.edu
SWOG-S1602	NCT03091660	Porten, Sima	A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer	Treatment	1-877-827-3222
16803	NCT03209440	Rabow, Michael	Palliative Care for Elderly Outpatients	Supportive Care	austin.fan@ucsf.edu
127536		Ewing, Cheryl	Evaluation of Intra-Operative Ultrasound Guided Excision using the Hydromark Clip as an Alternative to Needle Localization for Non-Palpable Breast Lesions	Other	1-877-827-3222
20925	NCT04565327	Wang, Jane Zhen	Hyperpolarized ¹³ C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma	Diagnostic	namasvi.jariwala@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
160814	NCT02617407	Den Besten, Pamela	Pilot Study: Oral Microbiome and Dental Plaque Control with Livionex Dental Gel in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)	Prevention	janelle.urata@ucsf.edu
182010	NCT03669718	Algazi, Alain	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)	Treatment	carter.hultman@ucsf.edu
19259	NCT03590652	Shah, Nina	Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)	Treatment	1-877-827-3222
19958	NCT04257110	Munster, Pamela	A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Expressing Solid Tumors	Treatment	melissa.lopez@ucsf.edu
EA-MAP-12519-ANDREADIS	NCT03601442	Andreadis, Charalambos	Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release	Other	1-877-827-3222
20205	NCT04220866	Algazi, Alain	A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy	Treatment	1-877-827-3222
202015	NCT04590963	Algazi, Alain	A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor	Treatment	1-877-827-3222
13802	NCT01833806	Bucknor, Matthew	A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain	Supportive Care	1-877-827-3222
202010	NCT04272333	Ha, Patrick	A Phase 0 Study Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Motolimod Singly and in Combination with Nivolumab in Patients with Head and Neck Cancer	Basic Science	madeleine.welsh@ucsf.edu
189513	NCT03948763	Munster, Pamela	A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma	Treatment	denisha.otis@ucsf.edu; nana.owusu-kwarteng@ucsf.edu
19955	NCT03928314	Munster, Pamela	An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors	Treatment	1-877-827-3222
186515	NCT04149249	Walsh, Judith	CONNECT: Smoking Cessation and Lung Cancer Screening	Health Services Research	1-877-827-3222
20922	NCT04346225	Aggarwal, Rahul	Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer	Diagnostic	patricia.li@ucsf.edu; priscilla.chan2@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
161016	NCT04540107	Chang, Susan	Non-Invasive Characterization of Lower Grade Glioma	Diagnostic	1-877-827-3222
19107	NCT04006119	Oberheim Bush, Nancy Ann	A Phase II Study of Ad-RTS-hIL-12 + Velelimex in Combination with Cemiplimab-rwlc (Libtayo®) in Subjects with Recurrent or Progressive Glioblastoma	Treatment	Meghan.Tedesco@ucsf.edu
16751	NCT03011684	Rosen, Mitchell	Fertility Preservation Using Tamoxifen or Letrozole in Estrogen Sensitive Tumors Trial (TALES Trial)	Supportive Care	Flor.Juarez-Hernandez@ucsf.edu
CTSU-NRG-HN005	NCT03952585	Yom, Sue	A Randomized Phase II/III Trial Of De-Intensified Radiation Therapy For Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer	Treatment	carter.hultman@ucsf.edu
177017	NCT03435796	Shah, Nina	LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH CAR T CELLS	Treatment	Julie.McCluggage@ucsf.edu
18863	NCT03767348	Tsai, Katy	An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors	Treatment	arielle.oglesby@ucsf.edu
19703	NCT04545762	Andreadis, Charalambos	A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T cells for Treatment of Relapsed or Refractory Non Hodgkin Lymphoma	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
19704	NCT03884556	Friedlander, Terence	Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies	Treatment	Joanne.Otani@ucsf.edu; andrew.chon@ucsf.edu
197017	NCT04370509	Oh, David	A Phase II Study of Perioperative Pembrolizumab-Based Therapy in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma Prior to Cytoreductive Nephrectomy or Metastasectomy	Treatment	andrew.chon@ucsf.edu; carolyn.bridgman@ucsf.edu
19205	NCT04034225	Algazi, Alain	An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With ASPH+ Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck	Treatment	madeleine.welsh@ucsf.edu
19208	NCT04211337	Kang, Hyunseok	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Treatment	1-877-827-3222
192013	NCT04260126	Kang, Hyunseok	A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection	Treatment	1-877-827-3222
17755		Burke, Nancy	Catalyzing Breast Cancer Navigation for Survivorship Support: A pilot study	Health Services Research	1-877-827-3222
19089	NCT03509961	Higham, Christine	A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative	Treatment	magruderk@radonc.ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
20707	NCT04249947	Oh, David	A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Treatment	Joanne.Otani@ucsf.edu; andrew.chon@ucsf.edu
20708	NCT03625037	Andreadis, Charalambos	A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma	Treatment	andrew.chon@ucsf.edu
17656	NCT02623712	Smith-Bindman, Rebecca	The Watch the Spot Trial: A Pragmatic Trial of More Versus Less Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules	Diagnostic	janna.blaauw@ucsf.edu; lisa.tan@ucsf.edu
171022	NCT04044937	Hope, Thomas	Fluoroethyltyrosine for the evaluation of intracranial neoplasm	Diagnostic	namasvi.jariwala@ucsf.edu
19105	NCT04019002	Chang, Susan	Evaluating hyperpolarized and proton brain metabolism in patients with glioblastoma	Diagnostic	1-877-827-3222
19109	NCT04659811	Oberheim Bush, Nancy Ann	A Phase II Study of Stereotactic Radiosurgery in Conjunction with the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma	Treatment	1-877-827-3222
16753		Melisko, Michelle	A Pilot Study of the Pathways Program for Cancer Survivors at the UCSF Breast Care Center	Supportive Care	1-877-827-3222
17753	NCT03554044	Chien, Jo	A Phase 1b study of Talimogene Laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer with evidence of injectable disease in the locoregional area	Treatment	1-877-827-3222
187023	NCT03651271	Oh, David	An Exploratory Study of Nivolumab with or without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants with Advanced Metastatic Cancer	Treatment	Joanne.Otani@ucsf.edu; andrew.chon@ucsf.edu; eliot.lee@ucsf.edu
19521	NCT03869190	Friedlander, Terence	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma after Failure With Platinum-Containing Chemotherapy (MORPHEUS-mUC)	Treatment	patricia.li@ucsf.edu
19954	NCT03834948	Munster, Pamela	A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176	Treatment	1-877-827-3222
197012	NCT03288493	Shah, Nina	Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)	Treatment	Joanne.Otani@ucsf.edu; andrew.chon@ucsf.edu
20251	NCT04407442	Shah, Nina	Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with CD38 Monoclonal Antibody	Treatment	1-877-827-3222
197022	NCT04196491	Shah, Nina	A PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY OF BB2121 IN SUBJECTS WITH HIGH RISK, NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) (KarMMa-4)	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
19803	NCT04870320	Miaskowski, Christine	A Pilot Study of A Novel Cognitive Intervention for Cancer Survivors	Supportive Care	Karin.Snowberg@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
20208	NCT04541355	Kang, Hyunseok	Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation with Cisplatin	Supportive Care	madeleine.welsh@ucsf.edu
EA-RP6530-1803-AI	NCT03711604	Ai, Weiyun	Expanded Access: An Open Label, Compassionate Use Study of Tenzalisib (RP6530) in Patients Currently Receiving Treatment on Tenzalisib Trials in Hematological Malignancies	Treatment	1-877-827-3222
202014	NCT04588038	Kang, Hyunseok	A Window of Opportunity Trial of NT-17 in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage Surgery	Treatment	madeleine.welsh@ucsf.edu
CTSU-EA1151	NCT03233191	Freimanis, Rita	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	Screening	1-877-827-3222
18105	NCT03705351	Butowski, Nicholas	Safety and tolerability of tumor treating fields (TTFields) combined with chemoradiation in newly diagnosed glioblastoma (UNITY)	Treatment	Jane.Rabbitt@ucsf.edu
18857	NCT03528408	Tsai, Katy	Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma	Treatment	1-877-827-3222
19552	NCT03570619	Chou, Jonathan	IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations	Treatment	patricia.li@ucsf.edu
19851	NCT03815058	Daud, Adil	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA	Treatment	arielle.oglesby@ucsf.edu
19705	NCT03835533	Fong, Lawrence	A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
BMT-CTN-1703	NCT03959241	Damon, Lloyd	A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN #1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN #1801; Mi-Immune)	Prevention	1-877-827-3222
197016	NCT03970382	Oh, David	A PHASE 1A/1B, OPEN-LABEL FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY AND FEASIBILITY OF GENE-EDITED AUTOLOGOUS NeoTCR-T CELLS (NeoTCR-P1) ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH ANTI-PD-1 TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS	Treatment	Joanne.Otani@ucsf.edu; andrew.chon@ucsf.edu
194519	NCT04003636	Kelley, Robin	A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma	Treatment	kelly.bauer@ucsf.edu
SWOG-LUNGMAP	NCT03851445	Eftimie, Bogdan	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	Screening	1-877-827-3222
EA-KELLEY-08SEP20	NCT04507503	Kelley, Robin	Expanded Access: An Open-Label, Expanded Access Program of FUTIBATINIB in Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements	Other	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
19653	NCT04123535	Bucknor, Matthew	Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma	Treatment	lisa.tan@ucsf.edu
19101	NCT02655601	Butowski, Nicholas	A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001	Treatment	1-877-827-3222
20102	NCT04421378	Butowski, Nicholas	A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma	Treatment	1-877-827-3222
19702	NCT04061590	Gubens, Matthew	A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
19558	NCT03834506	Fong, Lawrence	A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)	Treatment	1-877-827-3222
AMC-103	NCT03603808	Wang, Chia-Ching	A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals	Treatment	1-877-827-3222
SWOG-S1418/BR006	NCT02954874	Eftimie, Bogdan	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy.	Treatment	chetali_gupta@whhs.com
20705	NCT04171843	Shah, Nina	A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, with or without nirogacestat, in Study Subjects with Relapsed/Refractory Multiple Myeloma	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
204511	NCT04597151	Piawah, Sorbarikor	Diet Education Among Colorectal Cancer Survivors in the Safety Net Setting: A Pilot Feasibility Study	Supportive Care	1-877-827-3222
19404	NCT03398655	Alvarez, Edwin	A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer	Treatment	1-877-827-3222
19407	NCT03894215	Ueda, Stefanie	A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS	Treatment	1-877-827-3222
184511	NCT03867916	Nguyen, Tung	The Patient Cancer Outreach, Navigation, Technology, and Support (Patient COUNTS) Project: Addressing Care for Asian Americans with Cancer	Health Services Research	1-877-827-3222
RTOG-1216	NCT01810913	Yom, Sue	Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck	Treatment	jamese.johnson@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
197010	NCT03907852	Oh, David	A PHASE 1/2 SINGLE ARM OPEN-LABEL CLINICAL TRIAL OF TC-210 IN PATIENTS WITH ADVANCED MESOTHELIN-EXPRESSING CANCER	Treatment	Julie.McCluggage@ucsf.edu; andrew.chon@ucsf.edu
19853	NCT03911869	Tsai, Katy	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis	Treatment	arielle.oglesby@ucsf.edu
19207	NCT04119453	Kang, Hyunseok	A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) of All Anatomic Sites of Origin	Treatment	1-877-827-3222
20551	NCT04471974	Aggarwal, Rahul	A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer	Treatment	1-877-827-3222
18801	NCT03905720	Chao, Maria	Non-pharmacologic approaches to relieve pain and symptom distress among diverse hospitalized cancer patients	Supportive Care	1-877-827-3222
NRG-BR004	NCT03199885	Eftimie, Bogdan	A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer	Treatment	chetali_gupta@whhs.com
207018	NCT03741127	Shah, Nina	Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101	Other	Joanne.Otani@ucsf.edu; andrew.chon@ucsf.edu
ECOG-ACRIN-EA2185	NCT04239573	Kirkwood, Kimberly	Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs	Health Services Research	Kristina.Johnson@UCSF.EDU